Description

(4aS,6S,8aR,8bR,10aR,11R,13aR,13bS)-6-(Acetyloxy)-5,6,7,8,8a,8b,10,10a,11,12,13,13a-dodecahydro-8a,10a-diMethyl-2-phenyl-11-[(1R,2E,4R)-1,4,5-triMethyl-2-hexen-1-yl]-4a,13b-etheno-1H,9H-benzo[c]cyclopenta[h][1,2,4]triazolo[1,2-a]cinnoline-1,3(2H)-dione is a highly complex, stereochemically defined organic compound belonging to a class of fused polycyclic structures. This compound is of significant interest for advanced pharmaceutical research and development, particularly in the synthesis of novel active pharmaceutical ingredients (APIs) and as a key chiral intermediate. It is primarily sought by pharmaceutical companies, contract research organizations (CROs), and academic research laboratories engaged in medicinal chemistry and process chemistry.

Application

• Pharmaceutical Intermediate: Serves as a critical chiral building block in the multi-step synthesis of complex drug candidates, particularly in oncology and central nervous system (CNS) therapeutic areas.
• Medicinal Chemistry Research: Used as a scaffold or precursor for structure-activity relationship (SAR) studies to develop new chemical entities with targeted biological activity.
• Process Development & Scale-up: Employed in the optimization and kilogram-scale production of advanced intermediates for clinical trial material (CTM) manufacturing.
• Reference Standard: Can be supplied as a high-purity analytical standard for method development, quality control, and regulatory filing support.
• Asymmetric Synthesis: Utilized in stereoselective synthesis due to its multiple defined chiral centers, enabling the construction of enantiomerically pure compounds.

Basic Information

Product Name	(4aS,6S,8aR,8bR,10aR,11R,13aR,13bS)-6-(Acetyloxy)-5,6,7,8,8a,8b,10,10a,11,12,13,13a-dodecahydro-8a,10a-diMethyl-2-phenyl-11-[(1R,2E,4R)-1,4,5-triMethyl-2-hexen-1-yl]-4a,13b-etheno-1H,9H-benzo[c]cyclopenta[h][1,2,4]triazolo[1,2-a]cinnoline-1,3(2H)-dione
CAS No.	60324-76-7
Molecular Formula	C41H48N4O4
Molecular Weight	660.85 g/mol
Synonyms	6-Acetoxy-11-[(1R,2E,4R)-1,4,5-trimethyl-2-hexen-1-yl]-8a,10a-dimethyl-2-phenyl-4a,13b-etheno-1H,9H-benzo[c]cyclopenta[h][1,2,4]triazolo[1,2-a]cinnoline-1,3(2H)-dione; CAS 60324-76-7; Benzo[c]cyclopenta[h][1,2,4]triazolo[1,2-a]cinnoline-1,3-dione derivative; Fused triazolocinnoline derivative; Advanced pharmaceutical intermediate 60324-76-7
EINECS	Contact for details

Quality Control

This high-value intermediate is produced and controlled under a strict quality management system. Each batch undergoes comprehensive analytical characterization to ensure identity, purity, and consistency. Standard testing includes HPLC for purity and chiral purity, NMR (1H, 13C) for structural confirmation, and mass spectrometry. We provide a detailed Certificate of Analysis (COA) with each shipment, documenting all test results against agreed specifications. Our quality commitment supports cGMP compliance for materials intended for pharmaceutical development.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as specified on the label or COA. Keep the container in a dry, well-ventilated area. For long-term storage, consider inert gas purging to maintain stability.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.